IQVIA Holdings Inc. $IQV Shares Sold by Candriam S.C.A.

Key Points

• Candriam S.C.A. reduced its stake in IQVIA Holdings Inc. by 3.3%, selling 4,867 shares to hold a total of 143,036 shares valued at approximately $25.2 million.
• IQVIA reported $4.02 billion in revenue for the quarter, surpassing analyst estimates, and had earnings per share (EPS) of $2.81, exceeding the consensus estimate of $2.77.
• Several analysts have increased their price targets on IQVIA stock, with a consensus price target now at $228.62, and seventeen analysts rating the stock as "Buy."

Candriam S.C.A. cut its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 143,036 shares of the medical research company's stock after selling 4,867 shares during the quarter. Candriam S.C.A. owned 0.08% of IQVIA worth $25,217,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Pacer Advisors Inc. boosted its holdings in IQVIA by 5,036.1% in the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock valued at $153,681,000 after purchasing an additional 854,732 shares during the period. JPMorgan Chase & Co. increased its holdings in IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after purchasing an additional 798,534 shares during the period. D. E. Shaw & Co. Inc. raised its position in IQVIA by 211.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company's stock valued at $189,691,000 after purchasing an additional 655,153 shares in the last quarter. Nuveen LLC purchased a new position in IQVIA in the first quarter worth approximately $76,328,000. Finally, Cadian Capital Management LP acquired a new position in IQVIA during the 4th quarter worth approximately $78,604,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on IQV shares. Evercore ISI increased their price target on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. Barclays increased their target price on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 23rd. Redburn Partners set a $188.00 price target on shares of IQVIA in a research note on Friday, May 23rd. Mizuho raised their target price on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Finally, Robert W. Baird increased their target price on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $228.62.

Insider Activity

In other news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

IQVIA Price Performance

Shares of NYSE IQV traded up $0.67 on Tuesday, hitting $188.69. The company's stock had a trading volume of 324,696 shares, compared to its average volume of 1,949,508. The stock has a 50 day moving average of $174.28 and a 200-day moving average of $167.82. The company has a market capitalization of $32.08 billion, a price-to-earnings ratio of 27.30, a price-to-earnings-growth ratio of 2.10 and a beta of 1.30. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.